The FDA handed a cardiac surgeon at Washington, D.C.-based Washington Hospital Center a warning letter for not having institutional review board (IRB) approval when recruiting some patients into a clinical trial.
During an Aug. 24 to Sept. 15, 2011, inspection, investigators found five subjects recruited into an investigational drug study had signed consent forms indicating the trial was IRB-approved. But according to the Sept. 28 letter posted recently online, IRB approval had expired in early May of that year. Patients were still being recruited through July, the letter adds.
Avoid making this or other costly mistakes in your next trial.
Learn How Not to Ruin a Perfectly Good Product With a Flawed Study Design at this all-new FDAnews webinar.
Receive practical and easy-to-use information that will guarantee further understanding of study design and aid in approvability of an investigational product. Plant to attend this Wednesday conference. Register today!